营收暴增555%，毛利率近80%，这家“减肥企业”要上市！

Core Viewpoint - Tangji Medical focuses on "non-surgical, non-injection" endoscopic minimally invasive intervention therapy, aiming to carve out a "third path" in the trillion-dollar weight loss market [2]. Company Overview - Tangji Medical, established in 2016, specializes in innovative medical device solutions for metabolic diseases such as obesity and type 2 diabetes [6]. - The company has received approval for its gastric bypass stent system (GBS), the world's first approved endoscopic intervention for obesity treatment [7]. Market Potential - The global weight loss market is polarized, with GLP-1 receptor agonists like Semaglutide on one end and traditional metabolic surgeries on the other. Tangji Medical occupies the middle ground [5][6]. - The global market for endoscopic weight loss and metabolic treatment devices is projected to grow from $162.3 million in 2024 to $831.8 million by 2029, with a compound annual growth rate (CAGR) of 38.7% [6]. Financial Performance - For the first nine months of 2025, the company reported revenue of 20.86 million yuan, a significant increase of 554.8% from 3.186 million yuan in the same period the previous year [10]. - The gross margin improved from 70.2% to 78.7% during the same period [10]. Cost Structure and Losses - Despite revenue growth, the company reported a net loss of 65.96 million yuan for the full year of 2024 and 54.94 million yuan for the first nine months of 2025 [12]. - Operating expenses for the first nine months of 2025 reached 69.76 million yuan, significantly exceeding revenue, with R&D expenses accounting for 46.6% of total expenses [12]. Financial Health - As of September 30, 2025, the company had a net cash outflow of 49.04 million yuan from operating activities and only 33.74 million yuan in cash and equivalents [13]. - The total liabilities stood at 106 million yuan, surpassing total assets of 77.75 million yuan, indicating a net debt situation [13].